Vaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving Average – Should You Sell?

Vaxart, Inc. (NASDAQ:VXRT) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.78 and traded as low as $0.76. Vaxart shares last traded at $0.78, with a volume of 895,348 shares changing hands.

Analysts Set New Price Targets

Separately, Oppenheimer began coverage on shares of Vaxart in a research note on Thursday, August 15th. They set an “outperform” rating and a $4.00 target price for the company.

Vaxart Price Performance

The business has a 50 day simple moving average of $0.85 and a 200 day simple moving average of $0.78. The company has a market capitalization of $137.81 million, a price-to-earnings ratio of -1.47 and a beta of 0.66.

Vaxart (NASDAQ:VXRT) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). The firm had revenue of $6.40 million for the quarter, compared to analysts’ expectations of $65.70 million. Vaxart had a negative net margin of 543.21% and a negative return on equity of 114.19%. During the same quarter last year, the business earned ($0.16) earnings per share. On average, equities research analysts predict that Vaxart, Inc. will post -0.47 EPS for the current year.

Institutional Investors Weigh In On Vaxart

Several large investors have recently added to or reduced their stakes in VXRT. Kingswood Wealth Advisors LLC purchased a new stake in shares of Vaxart during the first quarter worth $32,000. Tidal Investments LLC acquired a new position in Vaxart during the 1st quarter worth $56,000. Sequoia Financial Advisors LLC purchased a new stake in Vaxart during the 2nd quarter worth about $65,000. Monaco Asset Management SAM purchased a new stake in Vaxart during the 2nd quarter worth about $402,000. Finally, Millennium Management LLC raised its position in Vaxart by 110.8% in the 2nd quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock valued at $2,660,000 after purchasing an additional 2,095,274 shares in the last quarter. 18.05% of the stock is owned by hedge funds and other institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.